Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups

David Pasquier*, Luc Bidaut, Daniela Elena Oprea-Lager, Nandita M deSouza, David Krug, Laurence Collette, Wolfgang Kunz, Yazid Belkacemi, Maria Grazia Bau, Caroline Caramella, Lioe Fee De Geus-Oei, Alex De Caluwé, Christophe Deroose, Olivier Gheysens, Ken Herrmann, Isabelle Kindts, Michalis Kontos, Sherko Kümmel, Barbro Linderholm, Egesta LopciIcro Meattini, Ann Smeets, Orit Kaidar-Person, Philip Poortmans, Pelagia Tsoutsou, Nawale Hajjaji, Nicola Russell, Elżbieta Senkus, Jean Noël Talbot, Lale Umutlu, Vincent Vandecaveye, Joost J C Verhoeff, Willemien Menke van der Houven van Oordt, Helle D Zacho, Fatima Cardoso, Laure Fournier, Frederieke Van Duijnhoven, Frédéric E Lecouvet

*Kontaktforfatter

Publikation: Bidrag til tidsskriftReview (oversigtsartikel)peer review

9 Citationer (Scopus)

Abstract

Breast cancer remains the most common cause of cancer death among women. Despite its considerable histological and molecular heterogeneity, those characteristics are not distinguished in most definitions of oligometastatic disease and clinical trials of oligometastatic breast cancer. After an exhaustive review of the literature covering all aspects of oligometastatic breast cancer, 35 experts from the European Organisation for Research and Treatment of Cancer Imaging and Breast Cancer Groups elaborated a Delphi questionnaire aimed at offering consensus recommendations, including oligometastatic breast cancer definition, optimal diagnostic pathways, and clinical trials required to evaluate the effect of diagnostic imaging strategies and metastasis-directed therapies. The main recommendations are the introduction of modern imaging methods in metastatic screening for an earlier diagnosis of oligometastatic breast cancer and the development of prospective trials also considering the histological and molecular complexity of breast cancer. Strategies for the randomisation of imaging methods and therapeutic approaches in different subsets of patients are also addressed.

OriginalsprogEngelsk
TidsskriftThe Lancet. Oncology
Vol/bind24
Udgave nummer8
Sider (fra-til)e331-e343
ISSN1470-2045
DOI
StatusUdgivet - aug. 2023

Bibliografisk note

Funding Information:
We thank Carine D L Bavelaar-Croon, Béatrice Fournier, Tanja Marinko, Ann Marinus, Evangelia Razis, Sofia Vaz, and Séverine Marchant for their help with copyediting the manuscript. Ann Marinus and Beatrice Fournier organised the logistics of circulating the literature review and Delphi questions and centralising and analysing the answers, along with LC. There was no funding source for this study.

Publisher Copyright:
© 2023 Elsevier Ltd

Fingeraftryk

Dyk ned i forskningsemnerne om 'Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups'. Sammen danner de et unikt fingeraftryk.

Citationsformater